# HARMONi-7 (NCT06767514)

> Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

No report yet. It can be ordered.

- Drugs tested: ivonescimab
- Indication: first-line metastatic NSCLC with high PD-L1 expression

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06767514
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Summit Therapeutics
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Ivonescimab Injection; Pembrolizumab Injection
- Enrollment: 780
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression free survival (PFS)

## Indexed commentary on HARMONi-7 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 20 posts on X
- 2 YouTube videos
- 2 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=harmoni-7-nct06767514

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06767514", "email": "<work email>"}; the inbox owner confirms by the emailed link.